A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

作者
Andre Henri Goy,Radhakrishnan Ramchandren,Nilanjan Ghosh,Javier L Munoz,David Morgan,Nam Hoang Dang,Mark H. Knapp,Maria L. Delioukina,Edwin C. Kingsley,Anh Tran,Jerry Ping,Darrin M. Beaupre,Jutta Katrin Neuenburg,Jia Ruan
出处
期刊:Blood [Elsevier BV]
卷期号:128 (22): 473-473 被引量:7
标识
DOI:10.1182/blood.v128.22.473.473
摘要

Abstract Background: DLBCL is the most common subtype (30-40%) of non-Hodgkin lymphoma and 50-60% of patients (pts) are cured with standard R-CHOP therapy. Among pts who fail R-CHOP, only 10-20% experience prolonged disease-free intervals with high-dose chemotherapy and autologous stem cell transplant (SCT). In particular, pts relapsing within 12 months (mo) of diagnosis and/or refractory pts have a very poor outcome (Crump, ASCO 2016). In addition, many pts are SCT-ineligible due to advanced age and/or comorbidities (Friedberg, ASH Educ Program 2011). Therefore, R/R DLBCL represents a clear unmet medical need. Ibrutinib (ibr), a first-in-class, oral, once-daily inhibitor of Bruton's tyrosine kinase, has shown activity as a single agent in R/R DLBCL, particularly in the non-germinal center B-cell-like (non-GCB) subtype (Wilson, Nat Med 2015). Lenalidomide (LEN) is an immunomodulatory agent that has shown activity in combination with rituximab (RTX) in phase 2 studies of R/R DLBCL (Wang, Leukemia 2013). This multicenter, open-label, phase 1b/2 study is designed to evaluate the safety and efficacy of ibr in combination with LEN and RTX in pts with R/R DLBCL. Here, we report preliminary results of the phase 1b portion of the study. Methods: The primary objective of the phase 1b portion is to determine the maximum tolerated dose and/or recommended phase 2 dose of ibr in combination with LEN and RTX in R/R DLBCL using a modified 3+3+3 design; the secondary objective is overall response rate (ORR) (Cheson, J Clin Oncol 2007). In phase 2, efficacy of the combination will be evaluated in R/R non-GCB DLBCL. SCT-ineligible pts, aged ≥18 years with histologically confirmed R/R DLBCL after ≥1 prior therapy, ECOG PS <2, and no central nervous system disease or history of allogeneic SCT were included. Pts received once-daily ibr (560 mg) in combination with IV RTX 375 mg/m2 on Day (D)1 of each 28-day cycle for 6 cycles and escalating doses of LEN on D1-21 of each 28-day cycle: 15 mg starting dose = Dose Level 1 (Cohort 1), 10 mg de-escalation cohort = Dose Level −1 (Cohort −1), 15 mg re-escalation cohort = Dose Level 1 (Cohort 1+), and 20 mg Dose Level 2 (Cohort 2). Dose Level Review Committee (DLRC) meetings were held for each dose level. Results: Thirty-seven pts were treated across all cohorts; 20/37 had non-GCB/ABC (18 non-GCB, 2 ABC), 9/37 GCB, and 8/37 unknown DLBCL subtype;10/37 transformed disease (2 GCB, 3 non-GCB, 1 ABC, 4 unknown). Median age was 63 years (range 41-85); 16 pts (43%) were ≥65 years old. Median time from diagnosis was 14.3 mo. Pts had a median of 3 prior regimens (range, 1-5); 23 (62%) were considered refractory to their last regimen. Grade 3/4 adverse events (AEs) occurred in 29 (78%) pts. The most frequent (>10%) grade 3/4 AEs were neutropenia (32%), thrombocytopenia (14%) and maculopapular rash (11%). Any-grade serious AEs (SAEs) occurred in 15 (41%) pts (Table 1). Dose-limiting toxicities (DLTs) were observed in 5 (13%) pts (rash [2], neutropenia [2], sepsis [1]; Table 1). Due to 3 DLTs in Cohort 1, a cohort at Dose Level −1 was opened. As 1 DLT was observed at this dose level, re-escalation to higher levels (starting at 15 mg LEN) occurred. Twenty-four (65%) pts discontinued treatment due to disease progression (14/24), AE (8/24), and withdrawal of consent (2/24); 14 (38%) died, primarily due to progressive disease (n=9). Deaths due to AEs (n=4) included E. coli sepsis, cardiac arrest (after progression and subsequent antineoplastic therapy), pneumonia, and worsening DLBCL. Cause of death was unknown in 1 pt. In the response-evaluable population (Table 2), on 10 mg LEN (n=7), there were no responses. On 15 mg LEN (n=18, including 2 pts with DLTs who received ≤15 days of study drug), the ORR was 44%; there were 3 complete responses (CRs) and 5 partial responses (PRs, among them, 3 pts with refractory disease); 6/9 (67%) with non-GCB/ABC DLBCL responded (including all 3 CRs). On 20 mg LEN, 2 response-evaluable pts did not respond, other response evaluations are pending. Conclusions: Based on safety data from the phase 1b portion of the study and the DLRC recommendation, the phase 2 portion of the study is being initiated at the 20 mg LEN dose level in combination with RTX and ibr. Preliminary efficacy results demonstrate responses at 15 mg LEN and suggest that a dose level above 10 mg LEN might be needed to induce a response in R/R DLBCL. In summary, despite small pt numbers, the results seen in this high-risk refractory DLBCL population are encouraging. Disclosures Goy: Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Genentech: Research Funding; Acerta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; infinity: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Other: Writing support, Speakers Bureau; Johnson & Johnson: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Ghosh:Gilead: Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; SGN: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Genentech: Research Funding; TG Therapeutics: Research Funding. Dang:Eisai: Research Funding; Seattle Genetics: Research Funding; Novartis: Honoraria; Pharmacyclics LLC, an AbbVie Company: Research Funding; Valor: Research Funding; Oncomed Pharmaceuticals Inc: Research Funding. Knapp:Insys Therapeutics, Inc.: Consultancy, Other: Travel, Accommodations, Expenses; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding. Kingsley:Pharmacyclics LLC, an AbbVie Company: Equity Ownership; Gilead: Equity Ownership. Tran:Pharmacyclics LLC, an AbbVie Company: Employment, Other: Travel, Accommodations, Expenses; AbbVie: Equity Ownership. Ping:Exelixics, Inc.: Employment, Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership. Beaupre:AbbVie: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment, Other: Leadership; Travel, Accommodations, Expenses, Patents & Royalties, Research Funding. Neuenburg:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment. Ruan:Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pharmacyclics, LLC, an AbbVie Company: Research Funding, Speakers Bureau; Seattle Genetics: Consultancy, Research Funding, Speakers Bureau; Janssen: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
elo完成签到,获得积分10
1秒前
meilirenshengzcs完成签到,获得积分10
1秒前
Zeq完成签到,获得积分10
3秒前
3秒前
领导范儿的应助被直率的问薇采纳,获得10
3秒前
彭于晏的应助被假装超人会飞采纳,获得10
5秒前
zhangyujin完成签到,获得积分10
6秒前
星辰大海完成签到 ,获得积分10
6秒前
某某完成签到,获得积分10
7秒前
曲项向天歌完成签到,获得积分10
7秒前
WQ完成签到,获得积分10
7秒前
Guofa.完成签到 ,获得积分10
7秒前
7秒前
怡然猎豹完成签到,获得积分0
7秒前
7秒前
甜晞完成签到,获得积分10
8秒前
1281440966完成签到,获得积分10
8秒前
Iris完成签到,获得积分10
9秒前
吕小布完成签到,获得积分10
9秒前
道交法完成签到,获得积分10
9秒前
lxyz061524完成签到,获得积分10
10秒前
Bella完成签到 ,获得积分10
10秒前
柯科研完成签到,获得积分10
10秒前
杨杨得亿完成签到 ,获得积分10
11秒前
SUNYAOSUNYAO完成签到,获得积分10
12秒前
勋章完成签到 ,获得积分10
12秒前
chuzihang完成签到 ,获得积分10
12秒前
14秒前
wilson完成签到,获得积分10
14秒前
老猫头鹰完成签到,获得积分10
14秒前
lydiaabc完成签到,获得积分10
15秒前
sherry221完成签到,获得积分10
16秒前
甜美建辉完成签到 ,获得积分10
16秒前
bingbing完成签到,获得积分10
17秒前
清脆语堂完成签到 ,获得积分10
17秒前
川川完成签到 ,获得积分10
17秒前
精明凝海完成签到,获得积分10
17秒前
蒸制发布了新的文献求助10
17秒前
今天要早睡完成签到,获得积分10
18秒前
shuangjiang完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173417
求助须知:如何正确求助?哪些是违规求助? 9565672
关于积分的说明 21781022
捐赠科研通 7767561
什么是DOI,文献DOI怎么找? 3431575
关于科研通互助平台的介绍 2555853
邀请新用户注册赠送积分活动 2476763